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Transcriptional feedback in the insulin signalling
pathway modulates ageing in both Caenorhabditis
elegans and Drosophila melanogaster†
Dobril K. Ivanov,*a Irene Papatheodorou,ab Matthias Ziehma and
Janet M. Thorntona
Several components have been previously identified, that modulate longevity in several species,
including the target of rapamycin (TOR) and the Insulin/IGF-1 (IIS) signalling pathways. In order to infer
paths and transcriptional feedback loops that are likely to modulate ageing, we manually built a
comprehensive and computationally eﬃcient signalling network model of the IIS and TOR pathways in
worms. The core insulin transduction is signalling from the sole insulin receptor daf-2 to ultimately
inhibit the translocation of the transcription factor daf-16 into the nucleus. Reduction in this core
signalling is thought to increase longevity in several species. In addition to this core insulin signalling,
we have also recorded in our worm model the transcription factors skn-1 and hif-1, those are also
thought to modulate ageing in a daf-16 independent manner. Several paths that are likely to modulate
ageing were inferred via a web-based service NetEﬀects, by utilising perturbed components (rheb-1,
let-363, aak-2, daf-2;daf-16 and InR;foxo in worms and flies respectively) from freely available gene
expression microarrays. These included ‘‘routes’’ from TOR pathway to transcription factors daf-16,
skn-1, hif-1 and daf-16 independent paths via skn-1/hif-1. Paths that could be tested by experimental
hypotheses, with respect to relative contribution to longevity, are also discussed. Direct comparison of
the IIS and TOR pathways in both worm and fly suggest a remarkable similarity. While similarities in the
paths that could modulate ageing in both organisms were noted, diﬀerences are also discussed. This
approach can also be extended to other pathways and processes.
1. Introduction
The ageing process, defined as a decrease in the ability of organisms
to respond to environmental stimuli, stress, decline in physiological
functions and inevitable death, is a pliable biological process.
Interventions, such as dietary restriction (DR, reduction in
calorie intake without malnutrition), have been previously
shown to robustly extend lifespan in a range of species, from
yeast to mammals and possibly primates.1 Inevitably, there is a
general interest in interventions and mechanisms that underlie
or aﬀect longevity in humans, despite the restrictions on experi-
mental interventions or genetic manipulations. Because of long
life expectancy, the use of primates as a proxy to humans, to
investigate potential mechanisms of ageing is a lengthy process.1
However, some of the mechanisms are conserved over large
evolutionary distances2 and therefore the use of short-lived
model organisms is a fruitful and convenient choice.
Several components and biological pathways have been
identified that modulate the ageing process, including nutrient
sensing pathways, the target of rapamycin (TOR)3,4 and the
insulin/insulin-like growth factor (IIS) signalling.5 Moreover,
the first pathway discovered which can regulate ageing is the IIS
pathway in the roundworm Caenorhabditis elegans (reviewed in
Kenyon et al. 20116). Following these observations, genetic variants
in human orthologues of several worm IIS components, among
others the forkhead box class O transcription factor (FOXO, daf-16
in worms), have been found to be associated with exceptional
longevity in genome-wide association studies in humans (for a list
of genes and studies see Kenyon et al. 20116).
One of the most widely used techniques to study the role
of component proteins in a biological pathway in model
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organisms is the overexpression or knockout of specific genes,
followed by experimental determination of the eﬀects that such
perturbations cause. Numerous perturbations in the IIS signal-
ling pathway have been reported to aﬀect lifespan in several
species. In worms and flies these include, along with many
others, the insulin receptor InR7/daf-2,8,9 chico,10 skn-1,11 hif-1,11
Pi3K/age-1,12 foxo/daf-16,13,14 pha-415 and several components
of the TOR pathway.16 The insulin signalling pathway is a
neuroendocrine pathway that among other functions monitors
nutrients on the whole organism level.17 Similarly, the TOR
pathway is also a nutrient-sensing pathway, although it monitors
the levels of intracellular nutrients.
The basic observation in multiple organisms is that a
reduction in insulin signalling activity (either by interfering with
components of the pathway or partly by DR) extends lifespan. This
process is thought to proceed by increasing the translocation of
the FOXO transcription factor (daf-16 and foxo in worms and flies)
into the nucleus. In turn, FOXO modulates the expression of a
multitude of genes18 and the side eﬀect is extended lifespan. So,
predicting the eﬀects of gene interference is very complex.
Following several lines of evidence, multiple signals that
aﬀect the nutrient sensing properties within the IIS and TOR
pathways modulate ageing. In this paper we have made an
attempt to capture the current knowledge of the IIS and TOR
pathways in worm and how their modulation aﬀects longevity,
in data that we have collected in a consistent manner. This gave
the ability to programmatically explore and diﬀerentiate between
potential signalling ‘‘routes’’ within the IIS and TOR pathways
that ultimately lead to changes in longevity. We utilised publicly
available genome-wide gene expression microarray experiments
that perturb genes within the IIS and TOR pathways. We also
made inferences about paths, including transcriptional feedback
loops, which support or contradict the observed ageing pheno-
type (short and long-lived) in these experiments. Furthermore,
we have attempted a direct comparison between the eﬀects of
perturbation of orthologous genes in the worm and fly with
respect to longevity phenotype recorded in both organisms.
These experiments comprised daf-2;daf-16, rheb-1, let-363, aak-2
in worms and InR;foxo in Drosophila. Using our model and these
publicly available microarray studies we are able to draw infer-
ences with respect to several functionally important paths within
the IIS and TOR pathways. These included paths to longevity via
skn-1, daf-16/foxo and hif-1.
2. Materials and methods
2.1. A signalling network model of the insulin and TOR
pathways in C. elegans
In order to explore ‘‘routes’’ or paths within the IIS and TOR
pathways that could potentially modulate longevity, a compre-
hensive knowledge of the genes part of the two pathways and
their connectivity was required. Such knowledge, not only
needed to be organised in a computationally eﬃcient way of
representing the diﬀerent components, but also had to be
visually portrayed in a manner that humans can understand.
Thus, we built a signalling network model of the IIS and TOR
pathways by using GraphML, a modified version of the Exten-
sible Markup Language (XML), supported in the program yEd
(http://www.yworks.com). These allowed the required formal
interpretation and at the same time a graphical representation
of the pathways.
Building the model, i.e. genes and their interactions/
connections, of the two pathways required extensive literature
review of the existing knowledge by utilising at first several
review articles.5,6,19–22 In addition, primary sources based on
PubMed literature searches (http://www.ncbi.nlm.nih.gov/pubmed/),
utilising a permutations of the insulin and TOR pathways names
and gene symbols already recorded in themodel, were also followed.
Evidence suggesting components and their interactions were
always followed to their primary source and interactions
between components that were only suggestive or hypothetical
were omitted. Thus, only connections that were shown as
derived from experimental evidence were included. Protein–
protein interactions, based on yeast two-hybrid system or other
screens were also not included, due to the lack of directionality
of the connections.
An overview of the model of the worm IIS and TOR signalling
pathways in C. elegans and their interactions is presented in
Fig. 1. The graph comprises activation and inhibition relation-
ships between the protein components of the signalling network
in the IIS and TOR pathways. A detailed description of the
signalling is given in 3.1. In addition, all gene names and
associated WormBase/Ensembl identifiers, part of the model of
IIS and TOR pathways in worms, are listed in Table S1 (ESI†). All
references used to build the worm connections/interactions
within the TOR and IIS pathways are listed in Table S2 (ESI†).
2.2. Whole-genome expression datasets
Having built a comprehensive model of the IIS and TOR path-
ways, we wanted to explore potential transcriptional feedback
and paths that could modulate longevity. The most widely used
technique that provides information on the eﬀect of components
in biological pathways is gene knockout or overexpression of
specific genes. This is followed by microarray gene expression
experiments to study the eﬀect of these perturbations. For this
reason all gene names and symbols, part of the two worm
pathways, were used to search for available experiments in
ArrayExpress23 and GEO24 databases. These databases are a
comprehensive source of functional genomics experiments,
including gene expression studies. Since microarray experiments
are the most widely used technique to study the eﬀect of genes in
a particular biological pathway, we concentrated on microarray
gene expression studies to try to maximise available experiments.
In order to achieve consistent gene expression profiles across
experiments and across species, data on such experiments
needed to be in raw format to allow unified data analysis.
Moreover, only experiments that had recorded longevity as
phenotype were considered.
As a result, only four experiments were found during these
searches. In total there were three worm studies comprising
four whole wormmicroarray expression profiles and one whole fly
experiment. Visual representation of the perturbed components
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can be found in Fig. 3. The identifiers, perturbed genes,
references and phenotype outcome can be found in Table 1.
The four worm microarray experiments comprised RNAi (i stands
for double-stranded RNA interference) inhibition of the rheb-1
and let-363 genes, part of the TOR pathway, and loss-of-function
mutations in daf-2 and daf-16, part of the core IIS pathway. An
overexpression of aak-2 (TOR pathway) was also included. The
whole fly experiment comprised loss-of-function mutations in
InR and foxo.
Analysis of diﬀerentially expressed genes for each experi-
ment was performed using the R programming language.
Initial quality control was performed using Relative Log Expres-
sion (RLE) values and Normalized Unscaled Standard Errors
(NUSE) boxplots, part of the aﬀyPLM package.25 Thus, arrays
for a particular experiment were excluded from further analysis
if the interquartile range (IQR) in the NUSE boxplot were
outside +/1.05 and the IQR in the RLE boxplot exceeded
+/0.2. Raw data were then normalised and summarised using
the rma function,26–28 part of the aﬀy package,26,29 followed by
a quantile normalisation, part of the limma package.30 To
identify diﬀerentially expressed genes, linear models and the
empirical Bayes moderated t-statistic were used, as implemented
in the limma package. Diﬀerentially expressed genes were identi-
fied as exhibiting an adjusted p-value of o0.005 for all worm
experiments and o0.001 for the fly experiment (correction
applied: Benjamini and Hochberg or ‘‘BH’’ in the limma package).
Fig. 1 Overview of worm insulin and TOR pathways. Legend: rectangles represent genes; diamonds – molecules; triangles – environmental eﬀects; trapezoids – other
than IIS or TOR pathways; octagons – transcription factors; green arrow lines represent activation; red t-shaped lines represent inhibition; brown boxes starting with c_
represent complexes.
Table 1 Identifiers for the worm and fly experiments
Perturbed
components (Fig. 3) ArrayExpress ID GEO ID
Reference
(PubMed ID) Background Experiment Longevity
1 E-GEOD-1762 GSE1762 1530866368 daf-2 (e1370,m577) daf-2(e1370,m577);daf-16(df-50) Short lived
2 E-GEOD-9682 GSE9682 1907923943 N2 (RNAi) rheb-1 (RNAi) Long lived
3 N2 (RNAi) let-363 (RNAi) Long lived
4 E-GEOD-25513 GSE25513 2133104469 N2 aak-2 (overexpression) Long lived
5 E-TABM-757 NA 2169471918 daGAL4>UAS-dInR
DN dfoxoD/D daGAL4>UAS-dInR
DN Short lived
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Only diﬀerentially expressed genes that are part of the IIS and
TOR pathways were considered in both worm and fly experiments.
2.3. NetEﬀects
In order to identify ‘‘routes’’ or paths that could potentially
modify the longevity phenotype in the abovementioned experi-
ments we used NetEﬀects as a tool for inferring the impact of
diﬀerential gene expression on the IIS and TOR pathways and
relating these inferences on the longevity phenotype. It has
been previously developed and tested to identify paths related
to longevity changes from fly mutants of the insulin/insulin-like
growth factor signalling pathway.31 NetEﬀects employs Answer
Set Programming (ASP), a method for declarative programming
that supports logic-based inferences. NetEﬀects was adapted to
analyse the IIS and TOR pathways in C. elegans in the same
fashion as the equivalent pathway for the fly described in
Papatheodorou et al. 2012.31 In addition, paths were classified
as ‘‘primary’’ or ‘‘secondary’’ by using the perturbed or diﬀeren-
tially expressed component/gene as starting point respectively.
The web-service for the C. elegans version of the IIS pathway is
available via http://www.ebi.ac.uk/thornton-srv/software/NetEf
fects/worm_path.php.
3. Results and discussion
3.1. A signalling network model of the Insulin and its
interaction with the TOR pathway
The single insulin receptor (daf-2) can be activated by at least 40
diﬀerent insulin-like (ins) peptides,32–34 following signals from
olfactory and chemosensory neurons. The activation of daf-2
leads to the recruitment of the insulin receptor substrate (ist-1),35
which in turn can activate the phosphoinositide-3-kinase (PI3K)
complex. The PI3K complex comprises the age-1 (PI3K-like
catalytic subunit) and aap-1 (PI3K-like adaptor subunit) proteins
and can also be directly activated by daf-2.35 Phospholipid
products of PI3K (phosphatidylinositol(3,4,5) triphosphate –
PIP3) can activate phosphoinositide-dependent kinase-1 (pdk-1),
leading to the activation of AKT/protein kinase B-like proteins
(akt-1 and akt-2) and serum and glucocorticoid-inducible kinase
(sgk-1). AKT-1, AKT-2 and SGK-1 kinases, separately and in the
form a complex (protein kinase B – PKB), antagonise the activity of
the forkhead transcription factor daf-16.36
This core signal transduction pathway receives input and is
modulated by a number of other proteins. These include, among
others, the worm orthologue of the human PTEN tumour
suppressor gene, daf-18 (ref. 37) that dephosphorylates the
phospholipid PIP3, thus limiting the activation of downstream
AKT-1/2 kinases. AKT kinases activity is also modulated by the
PP2A regulatory subunit (pptr-1)38,39 and c-Jun N-terminal
kinase (JNK)-interacting protein 1 (jip-1).40 Furthermore, activated
daf-16 can inhibit the transcription of at least one of the insulin-like
peptides (ins-7)33 and activate another (ins-18).41 These positive
and negative feedback loops are in eﬀect a self-regulation of
the core insulin signal transduction. However, it has to be
considered that transcriptional feedback operates on much
slower timescale compared to signalling processes.
The insulin pathway is highly connected and interacts with
several other pathways, such as ERK, p38MAPK, KGB, JNK, RAS,
notch and wnt signalling. In addition, it is also well connected
with the target-of-rapamycin (TOR) pathway, mainly via TORC2
and CeTORC1 complexes. The energy sensing AMP-activated
protein kinase (aak-2), part of the TOR pathway, is activated by
decreased energy or glucose levels (i.e. low AMP to ATP ratio),42
which in turn inhibits GTPase rheb-1, an upstream activator of
CeTOR (let-363).43 The CeTORC1 and TORC2 complexes are
thought to regulate fat metabolism, feeding, larval develop-
ment and growth.44,45
3.2. Paths that modulate longevity in worms
We built a model of the worm IIS and TOR pathways following a
literature review of the current (as of time of writing) knowledge
of the diﬀerent components, part of the two pathways. Connections
(i.e. transcriptional inhibitions and activations) were compiled
solely from experimental evidence, thus allowing inferences of
the eﬀect of perturbed genes to reproduce as closely as possible
the paths that could be operational in vivo. Despite the worm
pathway being as comprehensive as possible, enzymatic kinetics,
mRNA levels/half lives and post-transcriptional modifications
have not been included in the model. This was mainly due to a
lack of comprehensive and consistent data. Moreover, correlative
studies between mRNA and protein abundance suggest a
relatively medium degree of correlation.46–48 Thus, although
mRNA expression studies are somewhat easier to perform than
protein identification and quantification, they are only corre-
lative to the product of interest, i.e. proteins. An example of
such discrepancy within the IIS pathway is a transcriptional
feedback from FOXO to the insulin receptor InR, in Drosophila49
and mammals.50 In these experiments transcriptionally active
FOXO activates transcription of InR itself, but the two-fold
increase in the InR mRNA does not account for the five-six fold
increase in protein abundance.
Despite the basic pitfalls of this research, several important
paths and transcriptional feedback loops are relatively worthy
of further examination and these are described below. Although
there were other paths and subpaths that are likely to have an eﬀect
on longevity, the inferred eﬀects were considered too speculative.
Therefore, such paths are described in the supplementary results
(ESI†), along with graphs that illustrate the paths.
Several paths, parallel to the core insulin transduction signalling,
within the worm experiments considered, were found to support
or contradict the observed phenotype. If these are operational
within the cells, they could enhance or diminish the longevity
eﬀect of core insulin signalling via daf-16. At least according to
our model, these paths converge on two transcription factors,
i.e. hif-1 and skn-1.
3.2.1 Longevity path via hif-1. Lifespan extension of stabilised
hypoxia-induced transcription factor hif-1 appears to be IIS
independent51 and deletions of hif-1 have an eﬀect on longevity
in a temperature-dependent manner52 and are daf-16 dependent.
Four of the experiments (daf-2 vs. daf-2;daf-16, N2 vs. aak-2 oe, N2
vs. let-363i and N2 vs. rheb-1i) exhibited a common subpath in their
primary eﬀect (path starts from the perturbed component/gene).
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This path comprised an activation of the ribosomal protein S6
kinase (rsks-1) by CeTORC1 complex, which in turn activates
the hypoxia-induced factor (hif-1) and a potential hif-1mediated
increase in longevity (Fig. S1, S6 and S14, ESI†). The signalling
in this particular common path in some of the experiments was
likely increased (daf-2 vs. daf-2;daf-16) and in others decreased
(N2 vs. aak-2 oe, N2 vs. let-363i and N2 vs. rheb-1i), but in all of the
four experiments this path contradicted the observed phenotype.
Thus in the long-lived experiments (rheb-1i and let-363i) a
decreased activity of the CeTORC1 complex is likely to lead to a
decreased activity of hif-1 and a potential hif-1-mediated
decrease in longevity. It has to be said that although an
inhibition from hif-1 to daf-16 is recorded in the worm pathway
model, the current version of NetEﬀects only displays the
shortest path from the perturbed components to longevity.
While not displayed in NetEﬀects, the likely outcome from
a reduced hif-1 activity would be a decreased inhibition of
daf-16 and possible daf-16-mediated lifespan extension, as
previously shown under normoxic conditions.52 In the short-lived
daf-2;daf-16 experiment, a path comprising an activated CeTORC1
complex and a stabilised hif-1 (Fig. S1, ESI†), following a knock-out
of daf-16, is likely to oppose the observed reduction in longevity.
It would be interesting to investigate if removing such a path
(e.g. hif-1 RNAi), would result in further reduction in lifespan.
Additionally, for this particular experiment a likely skn-1 mediated
increase in longevity was also observed, due to the down-regulation
of akt-1/2 kinases, although a compensatory gsk-3 inhibition of
skn-1 was also likely to be increased (Fig. S4, ESI†).
3.2.2. Longevity paths via skn-1. The transcription factor
skn-1 is a stress-response gene that activates Phase 2 detoxifica-
tion response53 and mainly exerts its eﬀect in the intestine.54
Several lines of evidence suggest that the eﬀect of activated skn-1
could potentially modulate ageing and this could be achieved in
daf-16 independent manner. Our results suggest that a primary
path that leads to an increased longevity for two of the experi-
ments (N2 vs. let-363i and N2 vs. rheb-1i) involves skn-1. This path
exhibits a decreased activity of the CeTORC1 complex, subse-
quent decrease in the inhibitory link to skn-1 and daf-16 and an
increase in longevity, mediated by daf-16 and/or skn-1 (Fig. S5
and S9, ESI†). It is not obvious if the increased longevity in both
experiments is due to the synergistic nucleic accumulation of
both transcription factors. The sek-1 kinase, part of the p38
mitogen-activated protein kinase (MAPK), has been shown to be
required for skn-1 activation.11 Thus, a lifespan analysis of
double mutants (rheb-1i;sek-1i and let-363i;sek-1 as compared
to single mutants of rheb-1i and let-363i) is likely to shed some
light on the relative importance of skn-1 and daf-16 with respect
to the eﬀect on longevity from decreased activity of the TOR
pathway. Furthermore, two kinases sek-1 and jnk-1, part of the
p38 and JNK MAPKs, were up-regulated in both experiments,
suggesting a transcriptional feedback from TOR pathway to JNK.
These up-regulated kinases led to several paths that were likely
responsible for the skn-1 and daf-16 mediated increase in long-
evity, although this does not preclude the possibility of other
TOR-mediated independent of skn-1 and daf-16 longevity mechan-
isms, such as a reduction of mRNA translation, increased autophagy
or via the germline.55–57 An experiment of inhibited activity of
sek-1 kinase would also likely reduce the activation of skn-1 by
pmk-158 and the activation of daf-16 by jnk-1.59 If such experi-
ments are performed, according to our worm IIS and TOR
pathways model, the increased longevity phenotype of rheb-1i
and let-363i, would only result from a decreased inhibition of
daf-16 by the TOR pathway and a survival analysis would point
the relative contribution of skn-1. In support of such hypothesis
comes a study by Tullet et al. 2008 that has suggested an
independent of daf-16 pro-longevity phenotype of skn-1. Although,
as both transcription factors compete for binding to the negative
regulators akt-1, akt-2 and sgk-1, elimination of either one could
result in availability of these negative regulators.11
In these two experiments (rheb-1i and let-363i), several paths
that contradicted the increase in longevity were also revealed
(Fig. S8 and S12, ESI†). Some were due to a likely increased
IIS signalling by up-regulated insulin-like peptides. As the
observed phenotype was an increase in longevity, these paths
were found to contradict this phenotype. It would be interesting
to investigate the relative roles of increased IIS signalling and
decreased TOR signalling, with respect to the increase in longevity.
Similarly to the previous experiments proposed, a double
(daf-2;rheb-1 and daf-2;let-363) mutant could help delineate the
relative contribution of the increased IIS signalling and reduced
TOR signalling, with respect to the longevity phenotype.
3.3. A comparison with fly IIS and TOR signal transduction
pathways (InR vs. InR;foxo)
A direct comparison between the IIS and TOR pathways in both
flies and worms reveals that the two pathways are in general
evolutionarily conserved. The core components of the IIS are
present in both organisms, including the insulin/IGF-like
receptor, PI3K, PDK, AKT signal transduction kinases and the
forkhead box O (foxo) transcription factor. Diﬀerences are also
noticeable. There are at least 40 diﬀerent insulin-like peptides
in the worm as compared to only eight in the fly. These insulin-
like peptides agonise the sole insulin/IGF receptor (InR) in the
fly, where at least one insulin-like peptide (ins-18) in worms has
been shown to antagonise daf-241 and transcriptional feedback
loops from daf-16 to daf-2 have been shown. The majority of
components part of the TOR pathway are also relatively conserved
across the worm and fly. The TORC1/2 complexes are both
present, although there is not a worm orthologue of the tuberous
sclerosis complex (TSC).
As previously mentioned, the IIS and TOR pathways are
evolutionarily conserved in fly and worm.6,19 However, having
experiments of orthologous components in both the fly and
worm, now allowed us to compare the diﬀerences in the two
pathways and the eﬀect on longevity.
In the fly experiment (InR vs. InR;foxo) all possible paths (i.e.
primary and secondary) led only to a decrease in longevity,
supporting the observed phenotype (Fig. S17 and S18, ESI†).
This was to be expected, as in the IIS/TOR model in flies,
longevity is recorded as only modulated via foxo and foxo is
down-regulated in the experiment (Fig. 2).
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On the other hand, in our worm signalling model there are
several possible inputs into longevity. These comprise daf-16
(orthologue of the fly foxo), skn-1 and hif-1. Thus, other paths
that decrease longevity in the worm were observed, apart from
the daf-16/foxo mediated decrease in longevity, which was
observed in both experiments.
Several paths from the TOR pathway and the interaction with IIS
were observed to complement the observed decrease in longevity
(Fig. S17 and S18, ESI†). These paths were mainly down-regulating
S6k, followed by a decreased inhibition of chico and increased IIS
signalling. While an interaction between the IIS and TOR pathways
was shown in the worm experiment (reduced inhibition of CeTORC1
complex by daf-16, Fig. S1, S3 and S4, ESI†), this was not via rsks-1,
the worm orthologue of S6k. Furthermore, in the worm, the
transcription factors skn-1 and hif-1 were part of paths that were
likely to lead to an increase in longevity as compared to paths that
would result only in decrease in longevity in the fly experiment.
3.4. Transcriptional feedback in insulin signalling
The primary target of the worm and fly insulin-like peptides is
the sole insulin receptor34 InR in flies and daf-2 in worms,34 part
of the core IIS signal transduction pathway to ultimately inhibit
the nuclear translocation of the transcription factor daf-16/foxo.
For several of the microarray experiments, a consistent
transcriptional feedback to the insulin-like peptides was
evident. In the long-lived experiments (rheb-1i and let-363i),
there was a substantial number of up-regulated insulin-like
peptides (seven and nine in the let-363 and rheb-1 respectively),
as compared to the wild-type (N2). In these two worm experi-
ments out of the 40 there were altogether nine up-regulated
insulin-like peptides and seven of those were found in both
experiments. The overall eﬀect of the up-regulated insulin-like
peptides would be an increase in the core insulin signal
transduction, thereby leading to an overall inhibition of daf-
16 and/or skn-1, followed by a potential daf-16 and/or skn-1
mediated decrease in longevity.
Several insulin-like peptides were down-regulated in the daf-
2;daf-16 double mutant experiment as compared to daf-2 back-
ground (ins-33 and ins-35). Hence, the down-regulated insulin-
like peptides in this short-lived experiment would ultimately
reduce the core insulin signalling transduction. However, since
daf-2 and daf-16 are inhibited in this experiment, the transcrip-
tional feedback would appear dysfunctional.
The down-regulated insulin-like peptides could potentially
be explained by a positive feedback loop from daf-16. This has
been shown for ins-18,41 but crucially not for any of the other
up-regulated peptides pertinent to the results obtained in
this work.
In addition, the two of the perturbed components (i.e. rheb-1
and let-363) are part of the TOR pathway. Therefore, if a
transcriptional feedback from daf-16 to the insulin-like peptides
is indeed active then the eﬀect of the perturbed components
Fig. 2 Overview of the fly insulin and TOR pathways. Legend: rectangles represent genes; diamonds – molecules; triangles – environmental eﬀects; trapezoids – other
than IIS or TOR pathways; octagons – transcription factors; green arrow lines represent activation; red t-shaped lines represent inhibition; brown boxes starting with
c_ represent complexes.
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(i.e. rheb-1 and let-363) must converge on daf-16. Indeed, several
paths within these two experiments show a decreased inhibi-
tion of daf-16 by the CeTORC1 complex. Thus, a transcription-
ally active daf-16 could provide a positive feedback loop to the
insulin-like peptides.
Conversely, a negative transcriptional feedback in the
daf-2;daf-16 double mutant experiment that contradicted the
observed phenotype, was also observed. The ins-7 was up-regulated
and the likely outcome would be an overall increase in the core
insulin signalling and a likely daf-16 and/or skn-1 mediated
decrease in longevity. A previously suggested negative transcrip-
tional feedback from daf-16, could explain the observed
up-regulation of ins-7.33
In the fly experiment two of the Ilps were also down-
regulated (Ilp3 and Ilp6), nonetheless there is a paucity of
experimental evidence to suggest a transcriptional feedback
from the IIS similar to the worm. Still, it has been suggested
that a positive feedback loop from fly foxo could result in
the up-regulation of Ilp3 and Ilp560 and Ilp3 was found to be
up-regulated in the fly InR;foxo experiment.
Despite several lines of evidence, suggesting a transcrip-
tional feedback loop from daf-16/foxo, it is also possible that a
signal other than daf-16 or foxo could provide a transcriptional
feedback loop to the insulin-like peptides. Several of the paths
examined intersect on the transcription factor skn-1, shown to
inhibit one of insulin-like peptides (ins-7)33,61 and skn-1 sup-
pression coupled with a daf-28 induction has been suggested as
a negative transcriptional feedback.62 Furthermore, both ins-7
and daf-28 were found to be up-regulated in 2 of the experi-
ments, i.e. rheb-1i and let-363i. As a result, it is possible that
diﬀerential expression of at least some of the insulin-like
peptides in these experiments is due to skn-1.
As previously argued, the eﬀects of the inhibition of rheb-1
and let-363 RNAi experiments, could converge on daf-16 and/or
skn-1, hence providing positive or negative feedback to the
insulin-like peptides. This could explain the up- and down-
regulated insulin-like peptides in the double mutant daf-2;daf-16.
However, ins-7, daf-28 and several other insulin-like peptides
were found to be down-regulated in the rheb-1 and let-363
experiments. By this means if, ins-7 and daf-28 are indeed
under negative transcriptional control of daf-16/skn-1 and the
others under positive control, both up and down-regulated
insulin-like peptides would be expected, similarly to the double
mutant daf-2;daf-16.
Therefore, other mechanisms could also be responsible for
the diﬀerential insulin-like peptides regulation, similar to a
gene dosage eﬀect of ins-18 over other insulin-like genes.34
4. Conclusions
Drosophila melanogaster and Caenorhabditis elegans diverged
B990 million years ago.63 Thus, it is not surprising that several
cellular mechanisms and physiological processes exhibit
substantial diﬀerences between flies and worms. Flies have
relatively well diﬀerentiated brain, a heart, vascular system,
vision and hearing, where worms do not. In terms of cellular
processes, phagocytosis in C. elegans for example, does not
seem to play a role in microorganism clearance. On the other
hand apoptotic pathway defence response in flies has not yet
been reported within the innate immune response.64 The
sensory system in flies is substantially more complex than in
worms. It has been proposed that there are at least two sensory-
lifespan pathways present in flies with its genes expressed in
diﬀerent sensory neurons, in contrast to worms (for a detailed
review see Linford et al. 201165).
A general overview of the IIS and TOR pathways in the worm
and fly suggests remarkable similarities. This signifies the
importance of the nutrient sensing properties of the IIS and
TOR pathways. Even though both species occupy distinct
ecological niches, the molecular basis of nutrient sensing is
similar over large evolutionary distance. The core IIS signal
transduction pathway appears evolutionary conserved, although
some diﬀerences are noticeable. A major diﬀerence is the
absence of the Drosophila insulin receptor substrates (IRS) chico
and Lnk and the absence of the TSC complex, part of the TOR
pathway, although an equivalent IRS homolog, ist-1, is present
Fig. 3 Perturbed components in the worm and fly experiments.
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in worms. Unfortunately, due to the absence of corresponding
experiments in the fly we could not show similarities and/or
diﬀerences in the paths leading to longevity, apart from the
foxo-mediated eﬀect on longevity. There were some indications
of conserved transcriptional feedback mechanisms that are
very similar in both model organisms. That is, a transcriptional
feedback from foxo to the insulin-like peptides. One major
diﬀerence that would greatly influence any such comparison
is the lack of diﬀerent factors recorded in our fly pathway
model that could mediate longevity, apart from foxo. It is
possible that some of these factors are worm-specific. The
hypoxia-induced factor hif-1 is evolutionary conserved and
present in worms, flies and mammals,66 thus it is very likely
performing a homologous function similar to worms, although
a hif mediated eﬀect on longevity in flies remains to be seen.
On the other hand, the stress response gene skn-1 in worms
appears to be without a homolog inDrosophila, thus it is likely to be
worm-specific, although functional counterparts in mammals have
been previously described.67
The work presented here indicates that such approach is
useful in analysing the eﬀects of perturbed components within
the IIS and TOR pathways, with respect to the eﬀect on longevity.
Furthermore, this approach could be extended, as new knowl-
edge is accumulated, to other pathways that have an eﬀect on
lifespan or biological processes, such as autophagy.
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